Regulatory & Commercialisation

Navigate the intersection of compliance, market access, and strategic launch planning to bring approved therapies successfully to patients.

Nicole Dale

FDA Generic Peptides Guidance Sets New Expectations

Pharmatica visual of the FDA generic peptides guidance showing peptide molecular structure and regulatory assessment of generic peptide medicines.

Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.

Nicole Dale

AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?

Pharmatica image representing AI in pharmaceutical GMP manufacturing using machine learning, predictive maintenance, digital quality management, continuous manufacturing, and smart pharmaceutical production.

Learn how AI in pharmaceutical GMP manufacturing is improving quality, data integrity, predictive maintenance, and regulatory compliance in modern drug production.

Nicole Dale

FAST-EU Pilot: Can Europe Finally Accelerate Multinational Clinical Trials?

Pharmatica image representing the FAST-EU Pilot supporting multinational clinical trials through coordinated European regulatory collaboration, accelerating clinical trial approvals under the EU Clinical Trials Regulation (CTR).

The FAST-EU Pilot aims to accelerate multinational clinical trials through faster coordinated assessments, supporting Europe’s 2030 clinical research ambitions.

Nicole Dale

One Pivotal Trial for FDA Approval? Success Depends on Trial Design

Pharmatica image of a modern pharmaceutical regulatory affairs workspace representing documentation, compliance, and submission processes essential for FDA drug approval. The scene shows three binders labeled “Regulatory Affairs,” “Submissions,” and “Compliance” on a clean office desk with documents and a pen in the foreground, while a blurred meeting of professionals is visible through a glass wall in the background. The composition conveys administrative precision and regulatory science underpinning.

One pivotal trial for FDA approval could accelerate drug development, reshape clinical trial strategy, and change the pharmaceutical regulatory landscape.

Nicole Dale

Europe’s Life Sciences Strategy. A New Era of Innovation?

Pharmatica picture of European pharmaceutical innovation showing biotechnology research, advanced manufacturing, artificial intelligence, and regulatory collaboration supporting the European Life Sciences Strategy.

The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.

Nicole Dale

One Global CMC Dossier? Digital Regulatory Submissions

Pharmatica photo‑realistic representation of CMC regulatory submissions showing global data networks, secure digital dossier exchange, and pharmaceutical manufacturing integration — document binders, connected globe, red padlock cybersecurity icon, and industrial equipment with red‑capped vials illustrate digital CMC submissions, regulatory reliance, and manufacturing quality.

Discover how digital CMC regulatory submissions, cloud collaboration, and AI accelerate the modernisation of manufacturing approvals and global pharma operations.

Nicole Dale

FDA PreCheck Pilot Program to Build Manufacturing Readiness

Pharmatica image of regulatory inspectors reviewing digital drug manufacturing systems in a pharmaceutical production facility, illustrating the FDA PreCheck Pilot Program, manufacturing readiness, U.S. domestic drug manufacturing, and advanced pharmaceutical manufacturing.

The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.

Nicole Dale

FDA Master Protocol Guidance for Smarter Clinical Trials

Clinical research laboratory featuring a Master Protocol document, laboratory samples, and digital analytics, representing clinical trial efficiency for precision medicine research under the FDA Master Protocol guidance.

Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.

Nicole Dale

Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?

Operation TrialBlazer aims to reshape U.S. clinical trials by combining FDA regulatory innovation, digital technologies, and modern trial strategies to reclaim global leadership in pharmaceutical development.

Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.

Nicole Dale

FDA Registration for Drug Manufacturing Enters a New Era

Modern pharmaceutical manufacturing facility with stainless steel equipment, automated vial conveyor, and red digital data wave overlay symbolising FDA regulatory oversight and digital quality systems.

The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.

Nicole Dale

Digital Measures in Clinical Trials: FDA vs EMA Pathways

Clinician reviewing digital measures in clinical trials on a tablet, illustrating regulatory acceptance of digital health technologies, digital biomarkers, and FDA and EMA qualification pathways for modern clinical research.

Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.

Nicole Dale

FDA Draft Guidance on Gene Editing Safety (2026)

DNA double helix illustrating the FDA gene editing draft guidance 2026, highlighting next-generation sequencing (NGS) safety assessment, off-target editing analysis, genomic integrity testing, and regulatory requirements for cell and gene therapy development.

The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.

Content type